BGI Genomics Co Ltd (300676) — Cash Flow-to-Debt Ratio
BGI Genomics Co Ltd (300676) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-3.08 Million could theoretically repay 0% of its total liabilities (CN¥2.93 Billion) in one year. See 300676 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BGI Genomics Co Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BGI Genomics Co Ltd across 14 annual periods. Also explore 300676 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BGI Genomics Co Ltd (2012–2025)
Year-by-year debt coverage analysis for BGI Genomics Co Ltd. For market capitalisation and broader financial context, see BGI Genomics Co Ltd (300676) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | CN¥-63.21 Million | CN¥3.14 Billion | ▼ -168.8% |
| 2024 | 0.03x | CN¥95.72 Million | CN¥3.27 Billion | ▼ -74.2% |
| 2023 | 0.11x | CN¥408.77 Million | CN¥3.61 Billion | ▲ +260.3% |
| 2022 | 0.03x | CN¥130.88 Million | CN¥4.16 Billion | ▼ -93.9% |
| 2021 | 0.51x | CN¥2.48 Billion | CN¥4.81 Billion | ▼ -24.0% |
| 2020 | 0.68x | CN¥3.60 Billion | CN¥5.32 Billion | ▲ +357.7% |
| 2019 | 0.15x | CN¥224.25 Million | CN¥1.52 Billion | ▲ +908.7% |
| 2018 | 0.01x | CN¥14.69 Million | CN¥1.00 Billion | ▼ -94.9% |
| 2017 | 0.29x | CN¥243.66 Million | CN¥853.88 Million | ▼ -5.2% |
| 2016 | 0.30x | CN¥234.07 Million | CN¥777.52 Million | ▼ -32.1% |
| 2015 | 0.44x | CN¥328.68 Million | CN¥741.37 Million | ▲ +3268.0% |
| 2014 | -0.01x | CN¥-8.16 Million | CN¥583.40 Million | ▼ -134.3% |
| 2013 | 0.04x | CN¥36.70 Million | CN¥899.46 Million | ▼ -52.0% |
| 2012 | 0.08x | CN¥72.49 Million | CN¥853.31 Million | — |